Adjuvant Chemotherapy in Pancreatic Cancer View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2016

AUTHORS

John P. Neoptolemos , David Cunningham , Francesco Sclafani , Paula Ghaneh

ABSTRACT

Pancreatic cancer is one of the major causes of cancer death. Most patients present with advanced disease, and only 10–15% of patients can undergo resection. Survival after curative surgery is poor, as recurrences occur either locally or distantly. Adjuvant therapy has been employed in large randomized trials to treat systemic disease and hopefully improve the poor prognosis. Chemoradiation, chemotherapy using 5-fluorouracil/folinic acid (5FU/FA), S-1, gemcitabine or gemcitabine plus capecitabine, and combination therapy have all been used in the adjuvant setting. The results of the EORTC and ESPAC-1 trials have revealed that there is no survival advantage associated with adjuvant chemoradiation following resection for pancreatic cancer compared to no chemoradiation. There is no level 1 evidence, as yet that chemoradiation is superior to chemotherapy alone following surgery. Justification for the use of combination chemoradiation with follow-on chemotherapy is based on the results of an underpowered 1987 GITSG study, which closed prematurely and compared intervention to observation. The RTOG 9704 combination study did not demonstrate a survival difference between a 5FU-based regimen compared with a gemcitabine-based chemoradiation regimen. There is no completed randomized study comparing chemotherapy versus combination therapy. There is a clear survival advantage with adjuvant 5FU/FA and single-agent gemcitabine based on the results from the ESPAC-1 and CONKO-001 study, respectively. The ESPAC-3 trial showed that these adjuvant regimens are equally effective, but gemcitabine has a better toxicity profile. In contrast, in a Japanese population, the JASPAC-01 trial demonstrated the superiority of S1 over gemcitabine. Adjuvant combination chemotherapy with gemcitabine plus capecitabine has been recently shown to provide a survival advantage compared with gemcitabine alone in Western patients in the ESPAC-4 trial. Phase III studies investigating other combination chemotherapy regimens are ongoing and will possibly increase the number of treatment options in this setting. More... »

PAGES

1-34

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4939-6631-8_43-2

DOI

http://dx.doi.org/10.1007/978-1-4939-6631-8_43-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1090830980


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Professor of Surgery, Department of Surgery, University of Heidelberg", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Professor of Surgery, Department of Surgery, University of Heidelberg"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neoptolemos", 
        "givenName": "John P.", 
        "id": "sg:person.0750565077.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750565077.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, The Royal Marsden NHS Foundation Trust", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Medicine, The Royal Marsden NHS Foundation Trust"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cunningham", 
        "givenName": "David", 
        "id": "sg:person.01320161130.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Royal Marsden NHS Foundation Trust", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "The Royal Marsden NHS Foundation Trust"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sclafani", 
        "givenName": "Francesco", 
        "id": "sg:person.0653217174.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653217174.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Professor of Surgery, Department of Molecular and Clinical Cancer Medicine, University of Liverpool", 
          "id": "http://www.grid.ac/institutes/grid.10025.36", 
          "name": [
            "Professor of Surgery, Department of Molecular and Clinical Cancer Medicine, University of Liverpool"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ghaneh", 
        "givenName": "Paula", 
        "id": "sg:person.07372440237.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372440237.86"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2016", 
    "datePublishedReg": "2016-01-01", 
    "description": "Pancreatic cancer is one of the major causes of cancer death. Most patients present with advanced disease, and only 10\u201315% of patients can undergo resection. Survival after curative surgery is poor, as recurrences occur either locally or distantly. Adjuvant therapy has been employed in large randomized trials to treat systemic disease and hopefully improve the poor prognosis. Chemoradiation, chemotherapy using 5-fluorouracil/folinic acid (5FU/FA), S-1, gemcitabine or gemcitabine plus capecitabine, and combination therapy have all been used in the adjuvant setting. The results of the EORTC and ESPAC-1 trials have revealed that there is no survival advantage associated with adjuvant chemoradiation following resection for pancreatic cancer compared to no chemoradiation. There is no level 1 evidence, as yet that chemoradiation is superior to chemotherapy alone following surgery. Justification for the use of combination chemoradiation with follow-on chemotherapy is based on the results of an underpowered 1987 GITSG study, which closed prematurely and compared intervention to observation. The RTOG 9704 combination study did not demonstrate a survival difference between a 5FU-based regimen compared with a gemcitabine-based chemoradiation regimen. There is no completed randomized study comparing chemotherapy versus combination therapy. There is a clear survival advantage with adjuvant 5FU/FA and single-agent gemcitabine based on the results from the ESPAC-1 and CONKO-001 study, respectively. The ESPAC-3 trial showed that these adjuvant regimens are equally effective, but gemcitabine has a better toxicity profile. In contrast, in a Japanese population, the JASPAC-01 trial demonstrated the superiority of S1 over gemcitabine. Adjuvant combination chemotherapy with gemcitabine plus capecitabine has been recently shown to provide a survival advantage compared with gemcitabine alone in Western patients in the ESPAC-4 trial. Phase III studies investigating other combination chemotherapy regimens are ongoing and will possibly increase the number of treatment options in this setting.", 
    "editor": [
      {
        "familyName": "Neoptolemos", 
        "givenName": "John P.", 
        "type": "Person"
      }, 
      {
        "familyName": "Urrutia", 
        "givenName": "Raul", 
        "type": "Person"
      }, 
      {
        "familyName": "Abbruzzese", 
        "givenName": "James", 
        "type": "Person"
      }, 
      {
        "familyName": "B\u00fcchler", 
        "givenName": "Markus W.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4939-6631-8_43-2", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4939-6631-8", 
        "978-1-4939-6631-8"
      ], 
      "name": "Pancreatic Cancer", 
      "type": "Book"
    }, 
    "keywords": [
      "pancreatic cancer", 
      "survival advantage", 
      "combination therapy", 
      "ESPAC-1 trial", 
      "single-agent gemcitabine", 
      "CONKO-001 study", 
      "ESPAC-3 trial", 
      "JASPAC 01 trial", 
      "ESPAC-4 trial", 
      "combination chemotherapy regimens", 
      "large randomized trials", 
      "adjuvant combination chemotherapy", 
      "phase III study", 
      "level 1 evidence", 
      "better toxicity profile", 
      "clear survival advantage", 
      "curative surgery", 
      "adjuvant setting", 
      "adjuvant chemoradiation", 
      "combination chemoradiation", 
      "GITSG study", 
      "chemoradiation regimen", 
      "ESPAC-1", 
      "adjuvant chemotherapy", 
      "advanced disease", 
      "adjuvant therapy", 
      "adjuvant regimens", 
      "chemotherapy regimens", 
      "most patients", 
      "III study", 
      "randomized study", 
      "combination chemotherapy", 
      "randomized trials", 
      "systemic disease", 
      "poor prognosis", 
      "Western patients", 
      "treatment options", 
      "cancer death", 
      "folinic acid", 
      "survival differences", 
      "chemoradiation", 
      "toxicity profile", 
      "chemotherapy", 
      "gemcitabine", 
      "combination studies", 
      "patients", 
      "major cause", 
      "therapy", 
      "trials", 
      "cancer", 
      "Japanese population", 
      "capecitabine", 
      "resection", 
      "regimen", 
      "regimens", 
      "surgery", 
      "disease", 
      "EORTC", 
      "recurrence", 
      "prognosis", 
      "follow", 
      "study", 
      "setting", 
      "death", 
      "survival", 
      "intervention", 
      "cause", 
      "options", 
      "population", 
      "FA", 
      "evidence", 
      "differences", 
      "results", 
      "contrast", 
      "acid", 
      "profile", 
      "use", 
      "S1", 
      "number", 
      "advantages", 
      "observations", 
      "superiority", 
      "justification"
    ], 
    "name": "Adjuvant Chemotherapy in Pancreatic Cancer", 
    "pagination": "1-34", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1090830980"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4939-6631-8_43-2"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4939-6631-8_43-2", 
      "https://app.dimensions.ai/details/publication/pub.1090830980"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-09-02T16:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/chapter/chapter_211.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-4939-6631-8_43-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-6631-8_43-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-6631-8_43-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-6631-8_43-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-6631-8_43-2'


 

This table displays all metadata directly associated to this object as RDF triples.

185 TRIPLES      22 PREDICATES      108 URIs      101 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4939-6631-8_43-2 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N9194c87caf5d4be28b669039eee87d1f
4 schema:datePublished 2016
5 schema:datePublishedReg 2016-01-01
6 schema:description Pancreatic cancer is one of the major causes of cancer death. Most patients present with advanced disease, and only 10–15% of patients can undergo resection. Survival after curative surgery is poor, as recurrences occur either locally or distantly. Adjuvant therapy has been employed in large randomized trials to treat systemic disease and hopefully improve the poor prognosis. Chemoradiation, chemotherapy using 5-fluorouracil/folinic acid (5FU/FA), S-1, gemcitabine or gemcitabine plus capecitabine, and combination therapy have all been used in the adjuvant setting. The results of the EORTC and ESPAC-1 trials have revealed that there is no survival advantage associated with adjuvant chemoradiation following resection for pancreatic cancer compared to no chemoradiation. There is no level 1 evidence, as yet that chemoradiation is superior to chemotherapy alone following surgery. Justification for the use of combination chemoradiation with follow-on chemotherapy is based on the results of an underpowered 1987 GITSG study, which closed prematurely and compared intervention to observation. The RTOG 9704 combination study did not demonstrate a survival difference between a 5FU-based regimen compared with a gemcitabine-based chemoradiation regimen. There is no completed randomized study comparing chemotherapy versus combination therapy. There is a clear survival advantage with adjuvant 5FU/FA and single-agent gemcitabine based on the results from the ESPAC-1 and CONKO-001 study, respectively. The ESPAC-3 trial showed that these adjuvant regimens are equally effective, but gemcitabine has a better toxicity profile. In contrast, in a Japanese population, the JASPAC-01 trial demonstrated the superiority of S1 over gemcitabine. Adjuvant combination chemotherapy with gemcitabine plus capecitabine has been recently shown to provide a survival advantage compared with gemcitabine alone in Western patients in the ESPAC-4 trial. Phase III studies investigating other combination chemotherapy regimens are ongoing and will possibly increase the number of treatment options in this setting.
7 schema:editor N367192cd92044341bf8f7d26de3a9606
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf N8c44d01446e743c9a085ff91b23d3b1d
11 schema:keywords CONKO-001 study
12 EORTC
13 ESPAC-1
14 ESPAC-1 trial
15 ESPAC-3 trial
16 ESPAC-4 trial
17 FA
18 GITSG study
19 III study
20 JASPAC 01 trial
21 Japanese population
22 S1
23 Western patients
24 acid
25 adjuvant chemoradiation
26 adjuvant chemotherapy
27 adjuvant combination chemotherapy
28 adjuvant regimens
29 adjuvant setting
30 adjuvant therapy
31 advanced disease
32 advantages
33 better toxicity profile
34 cancer
35 cancer death
36 capecitabine
37 cause
38 chemoradiation
39 chemoradiation regimen
40 chemotherapy
41 chemotherapy regimens
42 clear survival advantage
43 combination chemoradiation
44 combination chemotherapy
45 combination chemotherapy regimens
46 combination studies
47 combination therapy
48 contrast
49 curative surgery
50 death
51 differences
52 disease
53 evidence
54 folinic acid
55 follow
56 gemcitabine
57 intervention
58 justification
59 large randomized trials
60 level 1 evidence
61 major cause
62 most patients
63 number
64 observations
65 options
66 pancreatic cancer
67 patients
68 phase III study
69 poor prognosis
70 population
71 profile
72 prognosis
73 randomized study
74 randomized trials
75 recurrence
76 regimen
77 regimens
78 resection
79 results
80 setting
81 single-agent gemcitabine
82 study
83 superiority
84 surgery
85 survival
86 survival advantage
87 survival differences
88 systemic disease
89 therapy
90 toxicity profile
91 treatment options
92 trials
93 use
94 schema:name Adjuvant Chemotherapy in Pancreatic Cancer
95 schema:pagination 1-34
96 schema:productId N7513151e86554a82a562c1b688025323
97 Nc14a8e88c3b84794a0162f8bcb79f6d8
98 schema:publisher Nff8025d1642e4c1ba61effb3e0a39f6e
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090830980
100 https://doi.org/10.1007/978-1-4939-6631-8_43-2
101 schema:sdDatePublished 2022-09-02T16:12
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher N925ca4f188194eedb9ddbdb45732c548
104 schema:url https://doi.org/10.1007/978-1-4939-6631-8_43-2
105 sgo:license sg:explorer/license/
106 sgo:sdDataset chapters
107 rdf:type schema:Chapter
108 N034bc02c615f4a4f978fb2050373772c rdf:first sg:person.01320161130.16
109 rdf:rest N268ef7eff05d469ba66ae206b890f25d
110 N268ef7eff05d469ba66ae206b890f25d rdf:first sg:person.0653217174.51
111 rdf:rest Ne116d78222024cac921b90e7c6164352
112 N3635735858a845dd86ac25a9976b69ab rdf:first Nd8ee8520a8a44a4f8e98c7b445828c40
113 rdf:rest Nf795ce5fa1314255bda153e8fefe7ca4
114 N367192cd92044341bf8f7d26de3a9606 rdf:first Ne9b9cb573fdc4bc8969d9fd00d42c09e
115 rdf:rest N3635735858a845dd86ac25a9976b69ab
116 N6b7316167ef24b2eb729644834b7843c rdf:first N886e5a89bfd140b68be1ef635440a600
117 rdf:rest rdf:nil
118 N7513151e86554a82a562c1b688025323 schema:name dimensions_id
119 schema:value pub.1090830980
120 rdf:type schema:PropertyValue
121 N886e5a89bfd140b68be1ef635440a600 schema:familyName Büchler
122 schema:givenName Markus W.
123 rdf:type schema:Person
124 N8c44d01446e743c9a085ff91b23d3b1d schema:isbn 978-1-4939-6631-8
125 schema:name Pancreatic Cancer
126 rdf:type schema:Book
127 N9194c87caf5d4be28b669039eee87d1f rdf:first sg:person.0750565077.18
128 rdf:rest N034bc02c615f4a4f978fb2050373772c
129 N925ca4f188194eedb9ddbdb45732c548 schema:name Springer Nature - SN SciGraph project
130 rdf:type schema:Organization
131 Nc14a8e88c3b84794a0162f8bcb79f6d8 schema:name doi
132 schema:value 10.1007/978-1-4939-6631-8_43-2
133 rdf:type schema:PropertyValue
134 Nd722679ba534495cbf7c6942697e6422 schema:familyName Abbruzzese
135 schema:givenName James
136 rdf:type schema:Person
137 Nd8ee8520a8a44a4f8e98c7b445828c40 schema:familyName Urrutia
138 schema:givenName Raul
139 rdf:type schema:Person
140 Ne116d78222024cac921b90e7c6164352 rdf:first sg:person.07372440237.86
141 rdf:rest rdf:nil
142 Ne9b9cb573fdc4bc8969d9fd00d42c09e schema:familyName Neoptolemos
143 schema:givenName John P.
144 rdf:type schema:Person
145 Nf795ce5fa1314255bda153e8fefe7ca4 rdf:first Nd722679ba534495cbf7c6942697e6422
146 rdf:rest N6b7316167ef24b2eb729644834b7843c
147 Nff8025d1642e4c1ba61effb3e0a39f6e schema:name Springer Nature
148 rdf:type schema:Organisation
149 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
150 schema:name Medical and Health Sciences
151 rdf:type schema:DefinedTerm
152 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
153 schema:name Oncology and Carcinogenesis
154 rdf:type schema:DefinedTerm
155 sg:person.01320161130.16 schema:affiliation grid-institutes:None
156 schema:familyName Cunningham
157 schema:givenName David
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16
159 rdf:type schema:Person
160 sg:person.0653217174.51 schema:affiliation grid-institutes:grid.5072.0
161 schema:familyName Sclafani
162 schema:givenName Francesco
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653217174.51
164 rdf:type schema:Person
165 sg:person.07372440237.86 schema:affiliation grid-institutes:grid.10025.36
166 schema:familyName Ghaneh
167 schema:givenName Paula
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372440237.86
169 rdf:type schema:Person
170 sg:person.0750565077.18 schema:affiliation grid-institutes:None
171 schema:familyName Neoptolemos
172 schema:givenName John P.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750565077.18
174 rdf:type schema:Person
175 grid-institutes:None schema:alternateName Department of Medicine, The Royal Marsden NHS Foundation Trust
176 Professor of Surgery, Department of Surgery, University of Heidelberg
177 schema:name Department of Medicine, The Royal Marsden NHS Foundation Trust
178 Professor of Surgery, Department of Surgery, University of Heidelberg
179 rdf:type schema:Organization
180 grid-institutes:grid.10025.36 schema:alternateName Professor of Surgery, Department of Molecular and Clinical Cancer Medicine, University of Liverpool
181 schema:name Professor of Surgery, Department of Molecular and Clinical Cancer Medicine, University of Liverpool
182 rdf:type schema:Organization
183 grid-institutes:grid.5072.0 schema:alternateName The Royal Marsden NHS Foundation Trust
184 schema:name The Royal Marsden NHS Foundation Trust
185 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...